文献速递心力衰竭与心肌病

心脏植入式电子装置术后三尖瓣反流进展及其对死亡与住院的影响

Progression of Tricuspid Regurgitation After Cardiac Implantable Electronic Device Implantation and Its Impact on Mortality and Hospitalization: A Single‐Center Cohort Study
RSS 订阅 · Journal of Cardiovascular Electrophysiology · 2026-10-13

本研究为单中心回顾性队列,纳入2005至2023年间303例接受心脏植入式电子装置(CIED)植入的患者,中位随访4.8年。术后12个月三尖瓣反流进展发生率为34.0%,进展与心血管住院和复合终点独立相关。进展至重度三尖瓣反流者死亡和住院风险更高。

要点

  • CIED术后12个月约三分之一患者出现三尖瓣反流至少1级进展。
  • 三尖瓣反流进展独立预测心血管住院,但不独立预测全因死亡。
  • 进展至重度三尖瓣反流者死亡和住院风险增高,提示需术后超声随访。

核心结论

  • CIED植入后第一年约三分之一患者出现三尖瓣反流进展,且进展独立预测心血管住院。
  • 进展至重度三尖瓣反流者死亡和心血管住院风险更高。

研究设计与样本

  • 单中心回顾性队列研究,纳入2005至2023年间303例接受CIED植入的患者。
  • 中位随访时间4.8年,基线及术后12个月行超声心动图评估三尖瓣反流严重程度。

主要发现

  • 三尖瓣反流进展103例(34.0%),消退33例(10.9%),稳定167例(55.1%),整体呈右移(p<0.001)。
  • 不同装置类型间进展存在差异(p=0.031),VVI-ICD亚组净进展最大(31.8%恶化 vs 6.9%改善,p<0.001),CRT-D消退率最高(18.8%)。
  • 随访期间死亡67例(22.1%),住院164例(54.1%)。
  • 三尖瓣反流总体进展不独立预测死亡(HR 1.118,p=0.693),但独立预测心血管住院(HR 1.640,p=0.003)及复合终点(HR 1.480,p=0.014)。
  • 未校正分析中,进展至重度三尖瓣反流(n=15)与死亡增加(HR 1.99,p=0.024)及心血管住院增加(HR 2.45,p<0.001)相关。

关键数值与推荐

  • 三尖瓣反流进展定义为较基线至少加重1级。
  • 主要终点为三尖瓣反流进展;次要终点为全因死亡、心血管住院、两者复合终点及进展至重度三尖瓣反流。

临床怎么用

  • CIED术后12个月应常规行超声心动图随访,重点评估三尖瓣反流有无进展。
  • 术后进展至重度三尖瓣反流者应视为高危人群,加强临床监测与管理。

局限性

  • 单中心回顾性设计,样本量303例,存在选择偏倚及残余混杂可能。
  • 三尖瓣反流进展与死亡的独立关联未达统计学意义,相关结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Introduction Tricuspid regurgitation (TR) progression is a recognized complication of cardiac implantable electronic device (CIED) implantation, yet its prognostic impact on long-term clinical outcomes remains incompletely defined. Methods and Results In this single-center retrospective cohort, 303 patients undergoing CIED implantation between 2005 and 2023 were followed for a median of 4.8 years. TR severity was assessed echocardiographically at baseline and 12 months. The primary endpoint was TR progression (≥ 1-grade worsening); secondary endpoints were all-cause mortality, cardiovascular hospitalization, their composite, and progression to severe TR, analyzed by Kaplan–Meier and Cox regression. TR progressed in 103 patients (34.0%), regressed in 33 (10.9%), and remained stable in 167 (55.1%), a net rightward shift (p < 0.001). Progression differed by device type (p = 0.031): among the larger subgroups, VVI-ICD showed the greatest net progression (31.8% worsened vs. 6.9% improved; p < 0.001) and CRT-D the highest regression (18.8%). During follow-up, 67 patients (22.1%) died and 164 (54.1%) were hospitalized. Overall TR progression was not independently associated with mortality (HR 1.118, p = 0.693) but independently predicted cardiovascular hospitalization (HR 1.640, p = 0.003) and the composite endpoint (HR 1.480, p = 0.014). On unadjusted analysis, progression specifically to severe TR (n = 15) was associated with increased mortality (HR 1.99, p = 0.024) and cardiovascular hospitalization (HR 2.45, p < 0.001). Conclusion TR progression occurs in approximately one-third of CIED recipients within the first year and independently predicts cardiovascular hospitalization. Progression to severe TR identifies a higher-risk subset, supporting routine post-implant echocardiographic surveillance.

来源:Journal of Cardiovascular Electrophysiology,查看原文。版权归原作者所有。

引用

  1. Journal of Cardiovascular Electrophysiology:Progression of Tricuspid Regurgitation After Cardiac Implantable Electronic Device Implantation and Its Impact on Mortality and Hospitalization: A Single‐Center Cohort Study

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。